COMMUNIQUÉS West-GlobeNewswire

Glass House Brands Announces Planned Retirement of Chief Financial Officer
29/09/2026
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated June 10, 2026, to its short form base shelf prospectus dated June 10, 2026. LONG BEACH, Calif. and [...]
IMUNON Converts $1.2 Million of Debt-to-Equity
29/09/2026
Unique investment vehicle provides efficient access to equity capital Outstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, [...]
Weight Watchers and Google Health Enterprise Launch New Collaboration to Enhance Engagement and Outcomes in Weight Health Programs
29/09/2026
Starting in the employer-sponsored market, eligible Weight Watchers members will gain access to Google Fitbit Air and Google Health Enterprise—connecting daily health behaviors with Weight Watchers' science-backed [...]
Precision Optics to Participate in the Lytham Partners Fall 2026 Investor Conference
29/09/2026
LITTLETON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace [...]
Beta Bionics to Announce Third Quarter 2026 Financial Results on October 27, 2026
29/09/2026
IRVINE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third [...]
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
29/09/2026
Incidence and prevalence of OPSCC continue to rise in the U.S. largely driven by HPV infection OPSCC is estimated to represent 1 in 2 head and neck cancer patients in the 2L+ setting in the U.S. with approximately 14, [...]
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
29/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug [...]
Claris Bio Announces Oral Presentations at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting and Eyecelerator @ AAO
29/09/2026
SAN FRANCISCO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Claris Biotherapeutics, Inc. , a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening conditions where limited or [...]
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
29/09/2026
U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S. TX2100 Phase 1a clinical trial [...]
DiFusion to Define Therapeutic Biomaterials Category at NASS 2026
29/09/2026
Red Theater presentation will distinguish conventional biotolerable implants from materials deliberately engineered to influence the host response and participate in healing AUSTIN, Texas, Sept. 29, 2026 (GLOBE NEWSWIRE [...]
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
29/09/2026
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate changes in blood- [...]
Apyx Medical Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
29/09/2026
Patients reported high satisfaction and visible improvements in skin elasticity, youthfulness, and radiance CLEARWATER, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or [...]
Phathom Pharmaceuticals Announces Initiation of Registrational Phase 3 Study of VOQUEZNA® (vonoprazan) for As-Needed Treatment of Non-Erosive GERD
29/09/2026
Initiation of registrational Phase 3 study of VOQUEZNA® (vonoprazan) for as-needed (PRN) use in Non-Erosive Reflux Disease (NERD) builds on previously reported positive Phase 2 data Topline results expected in the first [...]
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
29/09/2026
Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 TEL AVIV, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a [...]
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
29/09/2026
NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Noah Medical’s Galaxy System Enters Commercial Use in Asia with First Procedure Completed in Hong Kong
29/09/2026
SAN JOSE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Medical robotics innovator Noah Medical today announced the successful completion of its first commercial procedure in Asia using the Galaxy™ System at Prince of [...]
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
29/09/2026
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
29/09/2026
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patients Real-world evidence from more than 1,100 U.S. [...]
Silexion Therapeutics Announces Exercise of Warrants
29/09/2026
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS- [...]

Pages